Saturday, December 3, 2022


Biotechnology News Magazine

Clinical Trial and Studies

Medsenic Announces Positive Results of its Phase II Clinical Study with Arscimed® for the Rx of Chronic Graft Versus Host Disease

The primary endpoint of this prospective Phase II multicenterter, non-randomised study was the improvement of treatment response, i.e., complete or partial disease remission 6 months after GvHD diagnosis, with Arscimed® in combination with prednisone with or without cyclosporine.

Pharmaxis Announces 1st Patient Enrolled in Clinical Trial Studying a Potential New Treatment for Bone Marrow Cancer Myelogibrosis

Pharmaxis has completed site initiation at several Australian and South Korean hospitals and the first patient has been enrolled.

Galapagos and Gilead: Discontinue ISABELA Phase 3 Trials in IPF

February 10, 2021 Galapagos NV and Gilead Sciences decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients...

Biophytis Announces Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.